Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$85.65 USD

85.65
493,550

+2.10 (2.51%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $85.65 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why Investors Should Add Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on continued procedure recovery, solid execution and increasing traction around innovations.

Zacks Equity Research

3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Zacks Equity Research

QIAGEN (QGEN) Expands Enzyme Offering to Aid Laboratory

by Zacks Equity Research

QIAGEN is a one-stop shop for all research needs, including solutions for sample preparation, automation and bioinformatics with enzyme offering expansion.

Zacks Equity Research

National Vision (EYE) Plans to Open New Stores Amid Macro Woes

by Zacks Equity Research

National Vision (EYE) plans to continue executing core growth initiatives and further investing in competitive advantages.

Zacks Equity Research

Abbott (ABT) Expands in Electrophysiology With New FDA Nod

by Zacks Equity Research

Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.

Zacks Equity Research

3 Reasons to Hold Inspire Medical (INSP) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Inspire Medical (INSP) on the back of its product innovations.

Zacks Equity Research

BD's (BDX) Latest Product Launch to Boost Research Outcome

by Zacks Equity Research

BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting and allow researchers to answer complex biological questions.

Zacks Equity Research

Hologic (HOLX) Gets FDA Nod for Multiplexed Respiratory Test

by Zacks Equity Research

Hologic's (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.

Zacks Equity Research

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

Zacks Equity Research

Here's Why You Should Retain Humana (HUM) in Your Portfolio

by Zacks Equity Research

Humana (HUM) remains well-poised for growth, attributable to a growing customer base, numerous contract wins and solid cash-generating abilities.

Zacks Equity Research

Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval

by Zacks Equity Research

Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.

Zacks Equity Research

What's in the Cards for Medtronic (MDT) in Q4 Earnings?

by Zacks Equity Research

Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.

Zacks Equity Research

STERIS (STE) Continues to Face Dull Dental Sales, Margin Woes

by Zacks Equity Research

STERIS (STE) competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach.

Zacks Equity Research

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

Veeva Systems' (VEEV) New Launch to Improve Patient Outcomes

by Zacks Equity Research

Veeva Systems' (VEEV) new offering is expected to facilitate effective engagement with customers and KOLs for improved patient journeys.

Zacks Equity Research

Edwards Lifesciences' (EW) TAVR Study Outcome Favorable

by Zacks Equity Research

Edwards Lifesciences' (EW) latest findings of the study confirm the value of the Edwards Benchmark programme for standardizing clinical pathways for patients undergoing TAVR in Europe.

Zacks Equity Research

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) on its strong execution of strategies, disciplined cost management and revenue timing.

Zacks Equity Research

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Zacks Equity Research

BD's (BDX) New FDA Approval to Improve MRSA Diagnostics

by Zacks Equity Research

BD's (BDX) receipt of the latest FDA approval is likely to improve laboratory workflow.

Zacks Equity Research

Medtronic's (MDT) Global Market Share Strong, FX Headwind Stays

by Zacks Equity Research

Within cardiac rhythm management, Medtronic's (MDT) pacing business continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family.

Zacks Equity Research

LabCorp (LH) Expands Laboratory Relationship With New Pact

by Zacks Equity Research

LabCorp's (LH) recent partnership will expand healthcare access, offer advanced diagnostic tools and guarantee that both patients and doctors can afford the treatments they get.

Zacks Equity Research

NextGen (NXGN) Q4 Earnings Top Estimates, Revenues Surge Y/Y

by Zacks Equity Research

NextGen's (NXGN) fourth-quarter fiscal 2023 results reflect strength in both its revenue sources.

Zacks Equity Research

3 Reasons to Retain Masimo (MASI) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Zacks Equity Research

Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists

by Zacks Equity Research

For Alcon (ALC), in terms of end market, Surgical global cataract procedure growth varies significantly by region.